Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Ph II Trials of DPX-Survivac in Combination with Ketruda Yield Positive Results in Patients With Diffuse Large B-cell Lymphoma
Ph II Trials of DPX-Survivac in Combination with Ketruda Yield Positive Results in Patients With Diffuse Large B-cell Lymphoma
Ph II Trials of DPX-Survivac in Combination with Ketruda Yield Positive Results in Patients With Diffuse Large B-cell Lymphoma
Submitted by
admin
on September 18, 2018 - 9:47am
Source:
CP Wire
News Tags:
IMV Inc
diffuse large B-cell lymphoma
DPX-Survivac
Headline:
Ph II Trials of DPX-Survivac in Combination with Ketruda Yield Positive Results in Patients With Diffuse Large B-cell Lymphoma
snippet:
Two of the first four evaluable participants showed tumor regressions at the first on-treatment CT scan
DPX-Survivac has received fast-track status from FDA
It also has orphan drug status from the FDA and the EMA
Do Not Allow Advertisers to Use My Personal information
